For example, combining TRF1 or TRF2 inhibitors with DNA-damaging agents has been shown to enhance the therapeutic efficacy, leading to increased cancer cell death (Gobbini et al. 2014; Maciejewska et al. 2022). This evidence concerns the gene TERF1 and cancer.